Skip Navigation



eCAM Advance Access published online on June 30, 2006
eCAM, doi:10.1093/ecam/nel033
This Article
Right arrow Full Text (PDF) Freely available
Right arrowOA All Versions of this Article:
3/4/483    most recent
nel033v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Grassberger, M.
Right arrow Articles by Hoch, W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Grassberger, M.
Right arrow Articles by Hoch, W.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author (2006). Published by Oxford University Press. All rights reserved.
Received December 19, 2005
Accepted May 11, 2006

Original Article

Ichthyotherapy as Alternative Treatment for Patients with Psoriasis: A Pilot Study

Martin Grassberger 1 * and W. Hoch 1

1 Medical University of Vienna, Sensengasse 2, A-1090 Vienna, Austria

* To whom correspondence should be addressed.
Martin Grassberger, E-mail: martin.grassberger{at}meduniwien.ac.at


  Abstract

Ichthyotherapy (therapy with the so-called ‘Doctorfish of Kangal’, Garra rufa) has been shown to be effective in patients with psoriasis in the Kangal hot springs in Turkey. This study evaluates the efficacy and safety of ichthyotherapy in combination with short-term ultraviolet A sunbed radiation in the treatment of psoriasis under controlled conditions. We retrospectively analyzed 67 patients diagnosed with psoriasis who underwent 3 weeks of ichthyotherapy at an outpatient treatment facility in Lower Austria between 2002 and 2004. Main outcome measures are as follows: overall relative reduction in Psoriasis Area Severity Index (PASI) score; proportion of patients with an improvement in their PASI score of ≥75% (PASI-75) and ≥50% (PASI-50); patient-reported outcomes assessed with a custom questionnaire; and patient follow-up with a questionnaire sent out in March 2005. Safety was evaluated by reviewing adverse events and vital signs. Overall there was a 71.7% reduction in PASI score compared to baseline (P < 0.0001). Of the 67 patients studied, 31 (46.3%) achieved PASI-75 and 61 patients (91%) achieved at least PASI-50. Patients reported substantial satisfaction with the treatment. The reported mean remission period was 8.58 months [95% confidence interval (CI) 6.05-11.11]. A total of 87.5% of patients reported a more favorable outcome with ichthyotherapy, when asked to compare ichthyotherapy to other previously tried therapies. Sixty-five percent stated that after the relapse their symptoms were less severe than before treatment. There were no significant adverse events. The benefit demonstrated in this study along with the favorable safety profile suggests that ichthyotherapy could provide a viable treatment option for patients with psoriasis.

Keywords: Garra rufa; ichthyotherapy; Kangal fish; psoriasis treatment; ultraviolet A.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Journal Watch DermatologyHome page
Looking Far Afield . . .
Journal Watch Dermatology, August 24, 2007; 2007(824): 4 - 4.
[Full Text]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.